N Shaverdian1, J Beattie2, M Thor3, M Offin4, A F Shepherd5, D Y Gelblum5, A J Wu5, C B Simone5, M D Hellmann4, J E Chaft4, A Rimner5, D R Gomez5. 1. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA. Electronic address: shaverdn@mskcc.org. 2. Pulmonary Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. 3. Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, USA. 4. Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. 5. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.
Abstract
BACKGROUND: Immune checkpoint inhibitors (ICIs) and thoracic radiotherapy are increasingly used to treat advanced cancers. Despite data indicating exaggerated radiation toxicities in patients with autoimmune disease, the safety of thoracic radiotherapy in patients with prior ICI-associated immune-related adverse events (irAEs) is undefined. PATIENTS AND METHODS: Patients treated from 2014 to 2020 with ICIs were queried for receipt of corticosteroids and radiotherapy. Patients who received thoracic radiation after symptomatic irAEs were assessed for ≥grade 2 radiation pneumonitis (RP). Characteristics predictive of RP were assessed using logistic regression and response relationships were modeled. RESULTS: Among 496 assessed patients, 41 with irAE history subsequently treated with thoracic radiotherapy were analyzed. Most irAEs were grade 2 (n = 21) and 3 (n = 19). Median time from irAE onset to radiotherapy was 8.1 months. Most patients received stereotactic body radiation therapy (n = 20) or hypofractionated radiotherapy (n = 18). In total, 25 patients (61%) developed ≥grade 2 RP at a median of 4 months from radiotherapy and 11 months from onset of irAEs. Three months from RP onset, 16 of 24 (67%) assessable patients had persistent symptoms. Among patients with prior ICI pneumonitis (n = 6), five patients (83%) developed ≥grade 2 RP (grade 2, n = 3; grade ≥3, n = 2). The mean lung radiation dose (MLD) predicted for RP (odds ratio: 1.60, P = 0.00002). The relationship between MLD and RP was strong (area under the receiver-operating characteristic curve: 0.85) and showed an exaggerated dose-response. Among patients with an MLD >5 Gy (n = 26), 21 patients (81%) developed ≥grade 2 RP. CONCLUSION: This is the first study assessing the toxicity of radiotherapy among patients with prior irAEs from ICIs. Patients with prior irAEs were found to be at very high risk for clinically significant and persistent RP from thoracic radiotherapy. Careful consideration should be given to the possibility of an increased risk of RP, and close monitoring is recommended in these patients.
BACKGROUND: Immune checkpoint inhibitors (ICIs) and thoracic radiotherapy are increasingly used to treat advanced cancers. Despite data indicating exaggerated radiation toxicities in patients with autoimmune disease, the safety of thoracic radiotherapy in patients with prior ICI-associated immune-related adverse events (irAEs) is undefined. PATIENTS AND METHODS: Patients treated from 2014 to 2020 with ICIs were queried for receipt of corticosteroids and radiotherapy. Patients who received thoracic radiation after symptomatic irAEs were assessed for ≥grade 2 radiation pneumonitis (RP). Characteristics predictive of RP were assessed using logistic regression and response relationships were modeled. RESULTS: Among 496 assessed patients, 41 with irAE history subsequently treated with thoracic radiotherapy were analyzed. Most irAEs were grade 2 (n = 21) and 3 (n = 19). Median time from irAE onset to radiotherapy was 8.1 months. Most patients received stereotactic body radiation therapy (n = 20) or hypofractionated radiotherapy (n = 18). In total, 25 patients (61%) developed ≥grade 2 RP at a median of 4 months from radiotherapy and 11 months from onset of irAEs. Three months from RP onset, 16 of 24 (67%) assessable patients had persistent symptoms. Among patients with prior ICI pneumonitis (n = 6), five patients (83%) developed ≥grade 2 RP (grade 2, n = 3; grade ≥3, n = 2). The mean lung radiation dose (MLD) predicted for RP (odds ratio: 1.60, P = 0.00002). The relationship between MLD and RP was strong (area under the receiver-operating characteristic curve: 0.85) and showed an exaggerated dose-response. Among patients with an MLD >5 Gy (n = 26), 21 patients (81%) developed ≥grade 2 RP. CONCLUSION: This is the first study assessing the toxicity of radiotherapy among patients with prior irAEs from ICIs. Patients with prior irAEs were found to be at very high risk for clinically significant and persistent RP from thoracic radiotherapy. Careful consideration should be given to the possibility of an increased risk of RP, and close monitoring is recommended in these patients.
Authors: Jing Zhao; Ellen D Yorke; Ling Li; Brian D Kavanagh; X Allen Li; Shiva Das; Moyed Miften; Andreas Rimner; Jeffrey Campbell; Jinyu Xue; Andrew Jackson; Jimm Grimm; Michael T Milano; Feng-Ming Spring Kong Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-25 Impact factor: 7.038
Authors: David A Palma; Suresh Senan; Kayoko Tsujino; Robert B Barriger; Ramesh Rengan; Marta Moreno; Jeffrey D Bradley; Tae Hyun Kim; Sara Ramella; Lawrence B Marks; Luigi De Petris; Larry Stitt; George Rodrigues Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-09 Impact factor: 7.038
Authors: Charles Dolladille; Stéphane Ederhy; Marion Sassier; Jennifer Cautela; Franck Thuny; Ariel A Cohen; Sophie Fedrizzi; Basile Chrétien; Angélique Da-Silva; Anne-Flore Plane; Damien Legallois; Paul U Milliez; Véronique Lelong-Boulouard; Joachim Alexandre Journal: JAMA Oncol Date: 2020-06-01 Impact factor: 31.777
Authors: Narek Shaverdian; Maria Thor; Annemarie F Shepherd; Michael D Offin; Andrew Jackson; Abraham J Wu; Daphna Y Gelblum; Ellen D Yorke; Charles B Simone; Jamie E Chaft; Matthew D Hellmann; Daniel R Gomez; Andreas Rimner; Joseph O Deasy Journal: Cancer Med Date: 2020-05-06 Impact factor: 4.452
Authors: Kim Melanie Kraus; Caroline Bauer; Benedikt Feuerecker; Julius Clemens Fischer; Kai Joachim Borm; Denise Bernhardt; Stephanie Elisabeth Combs Journal: Cancers (Basel) Date: 2022-06-15 Impact factor: 6.575
Authors: David A Simon Davis; Ines I Atmosukarto; Jessica Garrett; Katharine Gosling; Farhan M Syed; Ben Jc Quah Journal: J Med Imaging Radiat Oncol Date: 2022-03-08 Impact factor: 1.667